Orion PharmaDHA:ORIONPHARM +1.41%69 FCF Yield % is 5.95 as of Jun. 27, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 438 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 65.53% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Orion Pharma's FCF Yield % or its related term are showing as below:
DHA:ORIONPHARM'
s FCF Yield % Range Over the Past 10 Years
Min: -15.12 Med: -0.36 Max: 26.31
Current: 5.95
During the past 12 years, the highest FCF Yield % of Orion Pharma was 26.31%. The lowest was -15.12%. And the median was -0.36%.
DHA:ORIONPHARM's FCF Yield % is ranked better than 65.53% of 438
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.54
vs DHA:ORIONPHARM: 5.95
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Orion Pharma FCF Yield % Related Terms
Orion Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: FCF Yield % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma FCF Yield % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a FCF Yield % of 5.95 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #151 out of 438 companies in the Utilities - Independent Power Producers industry, placing it in the top 34.5%.
Is Orion Pharma's FCF Yield % too high?
Orion Pharma's current FCF Yield % is 5.95. The Utilities - Independent Power Producers industry median FCF Yield % is 0.54. Orion Pharma's value of 5.95 is 1001.9% above this industry median. Based on the distribution chart, Orion Pharma ranks #151 out of 438 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's FCF Yield % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #151 out of 438 companies for FCF Yield %. This puts Orion Pharma in the upper half of its industry. The industry median FCF Yield % is 0.54. Orion Pharma's value of 5.95 is 1001.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for an Utilities - Independent Power Producers company?
The median FCF Yield % among Utilities - Independent Power Producers companies is 0.54, based on 438 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current FCF Yield % of 5.95 is 1001.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median FCF Yield % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current FCF Yield % is 5.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.38, compared to a current price of BDT28.80 — trading 41.3% above its estimated fair value. The current FCF Yield % is 5.95 and 1001.9% above the Utilities - Independent Power Producers industry median of 0.54. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current FCF Yield % is 5.95 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.80 is trading 41.3% above its estimated GF Value™ of BDT20.38.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
FCF Yield %: 5.95
GF Value™: BDT20.38 vs. price of BDT28.80 (41.3% above fair value)
Industry Position: 1001.9% above the Utilities - Independent Power Producers median (#151 of 438)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
